Cannabis Science (CBIS) Ready For A Prosperous And Healthy New Year: 'The Best Is Yet To Come'
Cannabis Science, Inc. (OTCQB: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, "is prepared to put the pedal to the metal" in 2015, in the words of Raymond C. Dabney, its Director, President & CEO and Co-Founder.
"We really want to offer a heartfelt 'thank you' to our investors and supporters for a great year in 2014," said Dabney. "We have come a long way and we believe we are ready to move to the next level in 2015, in terms of commercialization of our products, increased levels of public awareness and our ability to help address serious health issues not just in the U.S., but also in Africa, where we are becoming more active."
In Africa, Dabney, along with CBIS Senior Scientific Advisor Dr. Roscoe M. Moore, Jr., has initiated a partnership between CBIS and the Constituency for Africa (CFA) to help improve healthcare and health-related education infrastructure. Founded in 1990, the CFA has emerged as a leading organization for mobilizing public and private support for Africa in Washington, DC.
"Africa is just one example of how we're firing on all cylinders," Dabney said. "We think 2015 is going to be a special year."
In California, the company is in the final stages of preparation to launch new products such as extracts, oils, tinctures, tablets, and creams, thanks to the renegotiation of its agreement with Apothecary Genetics Investments LLC. The agreement enables Cannabis Science to purchase and license two northern California production farms with a combined total of 51 acres. The purchase included all related equipment for cannabis cultivation and production for the state's substantial medical cannabis market and gives Apothecary Genetics the right to sell Cannabis Science formulations throughout the State of California.
In Spain, the company is moving into 2nd stage cannabinoid production and is on track to deliver extensive data on CBD and THC levels, along with treatment regimes for many of its targeted ailments. "Our year-round growing capabilities give us the ability to meet the growing demand based on the number of delivery methods we are developing for various critical ailments," Mario S. Lap, Director and President of European Operations, said when the Spanish news was announced.
"We will be providing our formulation and developing scalability and portability for our pre-clinical programs that will target GMP production requirements. We're also working with and assisting in the creation of other patient groups in Spain and other countries to use formulations we develop," said Chad Johnson, Director and Chief Operating Officer. "These are only a few of our international operations planned to be rolled out in the New Year."
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.